LABU241122C135000
- 0.09
- -0.19-67.86%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Gilead Sciences Analyst Ratings
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Top 10 Most Expensive Stocks (Only 1 Gets a Quant Sell)
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Shares of Pharmaceutical Companies Are Trading Lower After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Express News | Biotechnology etf plunges! Pharmaceutical stocks collectively decline, with the United States Secretary of Health and Human Services nominee raising market concerns.
Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.
Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Cracking The Code: Understanding Analyst Reviews For Incyte
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Incyte Analyst Ratings